Mean (SD) age, years
|
37.8 (10.3)
|
37.1 (10.2)
|
Female, n(%)
|
392 (38.6%)
|
221 (43.6%)
|
Mean (SD) BMI, kg/m2
|
22.1 (3.2)
|
21.8 (3.2)
|
Education
|
Illiteracy, n(%)
|
50 (4.9%)
|
17 (3.4%)
|
Primary school, n(%)
|
97 (9.6%)
|
71 (14.0%)
|
Junior middle school, n(%)
|
445 (44.0%)
|
225 (44.4%)
|
Senior middle school, n(%)
|
252 (24.9%)
|
118 (23.3%)
|
University or higher, n(%)
|
168 (16.6%)
|
76 (15.0%)
|
Family annual income
|
0–30 000 Yuan
|
416 (41.1%)
|
198 (39.1%)
|
30 000–80 000 Yuan
|
327 (32.3%)
|
185 (36.5%)
|
80 000–120 000 Yuan
|
149 (14.7%)
|
75 (14.8%)
|
120 000–300 000 Yuan
|
66 (6.5%)
|
33 (6.5%)
|
300 000 Yuan and above
|
36 (3.6%)
|
10 (2.0%)
|
Current smoker, n(%)
|
234 (23.2%)
|
101 (20.0%)
|
Current alcohol drinker, n(%)
|
169 (16.8%)
|
70 (13.9%)
|
Self-reported pharyngitis, n(%)
|
228 (22.5%)
|
94 (18.6%)
|
Current use of psychotropic medicine, n(%)
|
15 (1.5%)
|
4 (0.8%)
|
Mean (SD) self-evaluated tolerancea
|
3.1 (0.9)
|
3.1 (0.9)
|
Mean (SD) expected level of discomforta
|
3.2 (0.9)
|
3.3 (0.9)
|
Mean (SD) level of anxiety before endoscopya
|
2.7 (1.2)
|
2.7 (1.2)
|
Pharyngeal sensitivity
|
Absent, n(%)
|
24 (2.8%)
|
8 (1.8%)
|
Attenuated, n(%)
|
75 (8.6%)
|
21 (4.8%)
|
Normal, n(%)
|
770 (88.6%)
|
406 (93.3%)
|
Mallampati classification
|
Class I, n(%)
|
231 (26.6%)
|
121 (27.8%)
|
Class II, n(%)
|
301 (34.7%)
|
145 (33.3%)
|
Class III, n(%)
|
164 (18.9%)
|
78 (17.9%)
|
Class IV, n(%)
|
171 (19.7%)
|
92 (21.1%)
|
Indication of endoscopy
|
Healthy physical examination
|
87 (8.6%)
|
42 (8.3%)
|
Suspected gastrointestinal disease
|
587 (57.8%)
|
288 (56.8%)
|
Gastrointestinal tumor warning symptoms
|
124 (12.2%)
|
77 (15.2%)
|
Various treatments under endoscopy
|
167 (16.5%)
|
83 (16.4%)
|
Lesions with regular follow-up
|
50 (4.9%)
|
17 (3.4%)
|
Endoscopy findings
|
Chronic gastritis
|
980 (96.6%)
|
479 (94.5%)
|
Peptic ulcer
|
95 (9.34%)
|
53 (10.5%)
|
Gastric polyps
|
147 (14.5%)
|
76 (15.0%)
|
Esophagus-gastric varices
|
86 (8.5%)
|
38 (7.4%)
|
Gastric cancer
|
45 (4.4%)
|
20 (4.0%)
|
Portal hypertensive gastropathy
|
31 (3.1%)
|
16 (3.2%)
|
Esophagus-gastric submucosal tumor
|
99 (9.7%)
|
57 (11.2%)
|